Biogen Idec recently announced that United States and European Union regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS).
The Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).
Environmental factors may contribute to up to a quarter of neurodevelopmental disorders, but more research into the role of specific substances is needed.
Epilepsy can be extremely challenging, but effective treatments are available and pharmacists can play an important role in counseling patients.
The precise mechanism of sudden unexplained death in epilepsy (SUDEP) remains a mystery, but researchers have discovered several contributing factors.
The new guidelines offer detailed information on interactions between antiepileptic drugs and antiretroviral drugs.
A social network for patients with life-changing conditions such as epilepsy is helping patients overcome social isolation and providing data for research.
Despite strict bioequivalence standards for generic drugs, concerns have persisted that generic antiepileptic drugs can cause problems for some patients.
Prime Therapeutics and EMD Serono entered into an agreement where patient adherence and health outcomes data determine whether or not rebates are given for a drug.
Yesterday Biogen Idec announced the company has submitted a New Drug Application (NDA) to the FDA for marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis (MS).
This complicated central nervous system disorder has many types and varying symptoms, and new treatments are available to help.
Pharmacies in the community setting have led the way in patient compliance, but have been largely ignored by MCOs and the pharmaceutical industry.
When insomnia begins to negatively impact a patient's quality of life, pharmacists can explain the nonpharmalogic and pharmalogic treatment options.
When insomnia begins to negatively impact a patient's quality of life, pharmacists can explain the nonpharmalogic and pharmalogic treatment options.
Exciting advances in the treatment of multiple sclerosis (MS) occurred in 2010 and continue as the MS pipeline remains robust.
This article will help patients with depression to understand their treatment options and know what to expect from their medications.
This article will help patients with depression to understand their treatment options and know what to expect from their medications.
New guidelines for managing patients with atrial fibrillation emphasize stroke prevention.
Stroke affects nearly 700,000 Americans a year. Emergency management is key to a positive patient outcome.
